NEW YORK A few weeks after Johnson & Johnson announced it would purchase the remainder of Dutch biotech firm Crucell it doesn't already own for about $2.4 billion, J&J received backing for the bid.
Crucell recommended the offer to the shareholders but not without receiving some criticism from shareholders Delta Lloyd Asset Management, Robeco and the Van Herk Group, which said the offer from J&J "undervalued" Crucell's worth. The fund managers jointly control at least 15.5% of Crucell, according to Reuters.
